91 related articles for article (PubMed ID: 1281762)
1. Differential isoform profiles of alpha 2-macroglobulin from plasma of patients with chronic-progressive or relapsing-remitting multiple sclerosis.
Back SA; Alhadeff JA
Clin Chim Acta; 1992 Oct; 211(1-2):27-36. PubMed ID: 1281762
[TBL] [Abstract][Full Text] [Related]
2. Altered isoelectric focusing of alpha 2-macroglobulin from plasma of patients with diabetes mellitus.
Back SA; Lorenzi M; Alhadeff JA
Clin Chim Acta; 1985 Jul; 150(1):21-9. PubMed ID: 2412734
[TBL] [Abstract][Full Text] [Related]
3. Differential isoelectric focusing properties of crude and purified human alpha 2-macroglobulin and alpha 2-macroglobulin-proteinase complexes.
Back SA; Alhadeff JA
J Chromatogr; 1983 Nov; 278(1):43-51. PubMed ID: 6198330
[TBL] [Abstract][Full Text] [Related]
4. Significantly increased fractions of transformed to total alpha2-macroglobulin concentrations in plasma from patients with multiple sclerosis.
Jensen PE; Humle Jørgensen S; Datta P; Sørensen PS
Biochim Biophys Acta; 2004 Nov; 1690(3):203-7. PubMed ID: 15511627
[TBL] [Abstract][Full Text] [Related]
5. Alteration of prolyl oligopeptidase and activated α-2-macroglobulin in multiple sclerosis subtypes and in the clinically isolated syndrome.
Tenorio-Laranga J; Peltonen I; Keskitalo S; Duran-Torres G; Natarajan R; Männistö PT; Nurmi A; Vartiainen N; Airas L; Elovaara I; García-Horsman JA
Biochem Pharmacol; 2013 Jun; 85(12):1783-94. PubMed ID: 23643808
[TBL] [Abstract][Full Text] [Related]
6. Effect of multiple sclerosis alpha 2-macroglobulin on mitogen induction of lymphocyte proliferation.
Rastogi SC; Clausen J
Immunobiology; 1985 May; 169(4):339-45. PubMed ID: 2408994
[TBL] [Abstract][Full Text] [Related]
7. Characterization of alpha 2-macroglobulin from plasma of cystic fibrosis patients and controls.
Back SA; Alhadef JA
Biochem Med; 1983 Aug; 30(1):34-42. PubMed ID: 6194793
[TBL] [Abstract][Full Text] [Related]
8. Assessment of protease-binding by alpha 2 macroglobulin in multiple sclerosis.
Bridges MA; Applegarth DA; Johannson J
Clin Chim Acta; 1982 May; 121(2):167-72. PubMed ID: 6178537
[No Abstract] [Full Text] [Related]
9. Aberrant forms of alpha(2)-macroglobulin purified from patients with multiple sclerosis.
Gunnarsson M; Stigbrand T; Jensen PE
Clin Chim Acta; 2000 May; 295(1-2):27-40. PubMed ID: 10767392
[TBL] [Abstract][Full Text] [Related]
10. Microheterogeneity of CSF alpha 2-macroglobulin in multiple sclerosis and other neurological diseases. A study performed by direct immunofixation after isoelectric focusing.
Mazzarello P; Poloni M; Pinelli P
Acta Neurol Belg; 1985; 85(4):222-8. PubMed ID: 2413703
[TBL] [Abstract][Full Text] [Related]
11. Cystic fibrosis alpha 2-macroglobulin protease interaction in vitro.
Parsons M; Romeo G
Clin Chim Acta; 1980 Jan; 100(3):215-24. PubMed ID: 6153299
[TBL] [Abstract][Full Text] [Related]
12. Abnormalities in native and dissociated alpha 2-macroglobulin isolated from multiple sclerosis serum.
Rastogi SC; Clausen J
Clin Chim Acta; 1980 Oct; 107(1-2):141-4. PubMed ID: 6159127
[No Abstract] [Full Text] [Related]
13. Purification and characterization of human alpha 2-macroglobulin conformational variants by non-ideal high performance size-exclusion chromatography.
Gonias SL; Roche PA; Pizzo SV
Biochem J; 1986 Apr; 235(2):559-67. PubMed ID: 2427074
[TBL] [Abstract][Full Text] [Related]
14. Ligand binding, conformational change and plasma elimination of human, mouse and rat alpha-macroglobulin proteinase inhibitors.
Gonias SL; Balber AE; Hubbard WJ; Pizzo SV
Biochem J; 1983 Jan; 209(1):99-105. PubMed ID: 6189480
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the structure and aspects of the proteinase-binding properties of cystic fibrotic alpha-macroglobulin with normal alpha 2-macroglobulin.
Roberts RC; Nelles LP; Hall PK; Salvesen GS; Mischler E
Pediatr Res; 1982 Jun; 16(6):416-23. PubMed ID: 6179035
[TBL] [Abstract][Full Text] [Related]
16. Differences between relapsing-remitting and chronic progressive multiple sclerosis as determined with quantitative MR imaging.
Miki Y; Grossman RI; Udupa JK; van Buchem MA; Wei L; Phillips MD; Patel U; McGowan JC; Kolson DL
Radiology; 1999 Mar; 210(3):769-74. PubMed ID: 10207480
[TBL] [Abstract][Full Text] [Related]
17. Clinical and laboratory features of in-patients with multiple sclerosis in a University Hospital in Tokyo from 1988-2002.
Tanaka K; Kujuro Y; Suzuki S; Tanahashi N; Hamada J; Nogawa S; Suzuki N
Intern Med; 2005 Jun; 44(6):560-6. PubMed ID: 16020880
[TBL] [Abstract][Full Text] [Related]
18. Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities.
Olerup O; Hillert J; Fredrikson S; Olsson T; Kam-Hansen S; Möller E; Carlsson B; Wallin J
Proc Natl Acad Sci U S A; 1989 Sep; 86(18):7113-7. PubMed ID: 2571150
[TBL] [Abstract][Full Text] [Related]
19. [Characteristics of the carbohydrate structure of alpha 2-macroglobulin in stomach cancer].
Smorodin EP; Kurtenkov OA
Eksp Onkol; 1986; 8(2):42-5. PubMed ID: 2421999
[TBL] [Abstract][Full Text] [Related]
20. Binding of transforming growth factor-beta 1 to methylamine-modified alpha 2-macroglobulin and to binary and ternary alpha 2-macroglobulin-proteinase complexes.
Hall SW; LaMarre J; Marshall LB; Hayes MA; Gonias SL
Biochem J; 1992 Jan; 281 ( Pt 2)(Pt 2):569-75. PubMed ID: 1371050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
